Madrigal pharmaceuticals provides corporate updates and reports third quarter 2023 financial results

Conshohocken, pa., nov. 06, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today provides a summary of recent corporate accomplishments, previews new phase 3 maestro study data scheduled for presentation at the aasld liver meeting, and reports third quarter 2023 financial results.
MDGL Ratings Summary
MDGL Quant Ranking